Medically reviewed by Jeffrey S. Lander, MD Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that makes the heart stiff and less flexible, making it harder for the heart to pump.ATTR-CM ...

ATTR amyloidosis results from the buildup of transthyretin in the body. It can be inherited or acquired and can affect your heart, kidneys, and nervous system. While there’s no cure, treatment can ...

ATTR phenotypes vary by genotype as well as by gene penetrance, age, and geographic location. A new analysis examined data from untreated, symptomatic patients who had 1 of 4 variants: F64L, I68L, ...

Pfizer is taking a curtain call for Vyndaqel, the low-dose version of its blockbuster tafamidis franchise for the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM). Pfizer will ...

Transthyretin amyloidosis (ATTR) is a protein conformational disorder caused by the build-up of transthyretin, the protein carrying thyroxine and retinol in the bloodstream. While cardiomyopathy is a ...

Transthyretin amyloidosis (ATTR) is not one disease, but a cluster of related conditions. At their core, they stem from a disorder that develops when normal proteins produced by the liver suddenly ...

Alnylam’s closely watched launch of its rare disease drug Amvuttra continued to outpace Wall Street expectations. Riding its March expansion into the heart condition of transthyretin amyloid ...

As transthyretin amyloid cardiomyopathy (ATTR-CM) progresses, it can cause more serious problems with the heart and other parts of the body. Talking with your doctor about how the condition may ...